BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

"We've had $180.6 million of Attruby sales in U.S. Attruby net product revenue this quarter," CEO Neil Kumar said, adding it was "a 24% growth from the last quarter" and "consistent with the brand ...

BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three ...

Shares of BridgeBio Pharma BBIO climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's AZN late-stage clinical setback boosted investor confidence in the company's sole marketed ...

BridgeBio received FDA approval for Attruby (acoramidis), a near complete TTR stabilizer (≥90%), approved to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients.

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx(R) Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by ...

Biotech company BridgeBio Pharma has announced that Sixth Street and HealthCare Royalty, a royalty acquisition company, ...

BridgeBio Pharma BBIO is moving from a launch-driven story toward a broader commercial execution test. Attruby has quickly become the company’s financial backbone, while late-stage pipeline assets ...